ArticleJACC. Case reports2025
Emergency Alcohol Septal Ablation for Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeft ventricular outflow tract obstruction (LVOTO) in hypertrophic cardiomyopathy (HCM) can result in severe cardiovascular complications, including the rare and life-threatening scenario of cardiogenic shock. CASE SUMMARY: A 74-year-old patient with advanced HCM presented with acute hemodynamic decompensation due to severe LVOTO. The patient was successfully managed with emergency alcohol septal ablation (ASA), resulting in rapid stabilization and symptom resolution. DISCUSSION: This case underscores the critical role of emergency ASA as an effective, minimally invasive treatment for high-risk patients with HCM with acute hemodynamic instability, especially when conventional surgical options are not feasible. The subsequent use of mavacamten further contributed to sustained improvement, highlighting the role of combined procedural and pharmacologic therapies in optimizing patient outcomes. TAKE-HOME MESSAGES: Emergency ASA is an effective, minimally invasive intervention for managing acute LVOTO in high-risk patients with HCM. Adjunctive use of mavacamten after ASA can further improve outcomes, highlighting the importance of combining procedural and pharmacologic therapies in managing high-risk HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.